$13.40
2.21% today
Nasdaq, Sep 16, 08:48 pm CET
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Pacira Pharmaceuticals, Inc. Stock price

$13.11
+0.71 5.73% 1M
-17.18 56.72% 6M
-20.63 61.14% YTD
-21.14 61.72% 1Y
-42.43 76.40% 3Y
-25.04 65.64% 5Y
-86.50 86.84% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.38 2.99%
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Key metrics

Market capitalization $604.72m
Enterprise Value $849.09m
P/E (TTM) P/E ratio 10.19
EV/FCF (TTM) EV/FCF 4.60
EV/Sales (TTM) EV/Sales 1.23
P/S ratio (TTM) P/S ratio 0.88
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth 3.15%
Revenue (TTM) Revenue $690.31m
EBIT (operating result TTM) EBIT $101.13m
Free Cash Flow (TTM) Free Cash Flow $184.74m
Cash position $404.23m
EPS (TTM) EPS $1.29
P/E forward 10.52
P/S forward 0.87
EV/Sales forward 1.23
Short interest 19.09%
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

3x Buy
33%
4x Hold
44%
2x Sell
22%

Analyst Opinions

9 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
33%
Hold
44%
Sell
22%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
690 690
3% 3%
100%
- Direct Costs 236 236
11% 11%
34%
454 454
13% 13%
66%
- Selling and Administrative Expenses 200 200
16% 16%
29%
- Research and Development Expense 79 79
8% 8%
11%
175 175
11% 11%
25%
- Depreciation and Amortization 74 74
17% 17%
11%
EBIT (Operating Income) EBIT 101 101
48% 48%
15%
Net Profit 64 64
1,491% 1,491%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the granting of inducement awards on September 4, 2024 to 17 new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into em...
Neutral
GlobeNewsWire
about one month ago
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid.
Neutral
Seeking Alpha
about 2 months ago
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 712
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today